
Last updated: 2026-10-13 17:28:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Propanc Biopharma, Inc. (PPCB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.42, with a market capitalisation of $4.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.41 to $47.50. This page covers its latest market performance, valuation, price trends and company information.
$4.77M | |
$0.43 | |
$67,500,000.00 | |
$0.41 | |
$0.44 | |
306.43K | |
1.82M | |
-- | |
$47.50 | |
$0.41 | |
-- | |
-- |
Propanc Biopharma, Inc. (PPCB) is currently trading at $0.42 as of 2026-10-13 17:25:00, down 5.00% ($0.02) from the previous close of $0.44
During today's regular trading session, PPCB has traded between $0.41 and $67,500,000.00, with a trading volume of 306.43K shares. The current price is near the lower end of today's range.
Over the past seven days, Propanc Biopharma, Inc. (PPCB) moved from $0.51 to $0.42, representing a decline of 17.64% ($0.09).
The stock traded between $0.41 and $0.53 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 260.78 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
PPCB is currently trading at $0.42, placing it 0.0% of the way from its 52-week low of $0.41 to its 52-week high of $47.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Propanc Biopharma, Inc. (PPCB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.